RougeTx

Vaderis Therapeutics

This company develops oral AKT inhibitor medicines for patients suffering from hereditary haemorrhagic telangiectasia and other rare vascular diseases.

Clotprotect Therapeutics

This company develops small molecule anti-fibrinolytic drugs for patients suffering from acute haemorrhage and severe bleeding.

Diagonal Therapeutics

This biotechnology company develops agonist antibody treatments for patients with rare genetic diseases like hereditary haemorrhagic telangiectasia and pulmonary arterial hypertension.

ClotProtect

This therapeutics company develops a small molecule drug to treat acute bleeding and improve survival for patients suffering from trauma or undergoing surgery.

Coagulant Therapeutics

This company develops medicines to treat acute bleeding conditions, such as postpartum haemorrhage and traumatic brain injury, for patients with urgent medical needs.

Scenic Biotech

This company develops disease-modifying small molecule therapeutics for patients with rare genetic and neurodegenerative disorders using its proprietary genetic modifier discovery platform.

Hemab Therapeutics

This biotechnology company develops prophylactic antibody-based therapies for patients with rare bleeding and thrombotic disorders such as Glanzmann thrombasthenia and von Willebrand disease.

Protego

This clinical-stage biotechnology company develops small molecule therapies that stabilise proteins to treat amyloidosis and other protein misfolding diseases for patients with organ damage.